Home › Esophageal Adenocarcinoma › New York › New York City
Esophageal Adenocarcinoma clinical trials in New York City, NY
18 studies for Esophageal Adenocarcinoma are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RecruitingPhase 2/3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
RecruitingPhase 3
- Manhattan Eye Ear and Throat Hospital, New York
- NYP/Weill Cornell Medical Center, New York
- Lenox Hill Hospital, New York
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
RecruitingPhase 2/3
- Memorial Sloan Kettering Cancer Center, New York
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RecruitingPhase 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
RecruitingPhase 2/3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Rockefeller Outpatient Pavilion (53rd Street), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
RecruitingPhase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
Recruiting
- Columbia Universtiy, New York
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecruitingPhase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RecruitingPhase 1
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
Recruiting
- Weill Cornell Medicine, New York
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Research Site, New York
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
RecruitingPhase 2
- Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Esophageal Adenocarcinoma trials in other cities
- Boston, MA13 studies
- Houston, TX12 studies
- Arlington, VA11 studies
- Nashville, TN11 studies
- Durham, NC10 studies
- Baldwin Park, CA9 studies
- Jacksonville, FL9 studies
- Rochester, MN9 studies
- St. Louis, MO9 studies
- Queens, NY9 studies
- Los Angeles, CA9 studies
- Pittsburgh, PA8 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.